Want to see HK:8189 full AI Analyst Report?
Top Page
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H
(8189)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.14
▼(-65.50% Downside)
Action:Upgraded
Date:10/21/26
The score is weighed down primarily by weak financial performance—persistent losses, very high and rising leverage, and consistently negative operating/free cash flow—despite the 2025 revenue rebound. Technicals further pressure the score, with price below major moving averages and negative MACD alongside very weak momentum. Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
2025 Revenue Rebound
The sharp 2025 revenue rebound shows that the company regained substantial top-line activity after a weaker period. Although profitability has not yet followed, renewed sales provide a larger operating base from which management could pursue scale, product development, and eventual margin improvement.
Negative Factors
Persistent Unprofitability
Profitability remains structurally weak despite the revenue rebound. Low and volatile gross margins, continuing operating losses, and a wider net loss indicate that additional sales are not yet translating into durable earnings. Without sustained margin improvement, growth may continue to consume rather than create value.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Rebound
The sharp 2025 revenue rebound shows that the company regained substantial top-line activity after a weaker period. Although profitability has not yet followed, renewed sales provide a larger operating base from which management could pursue scale, product development, and eventual margin improvement.
Read all positive factors
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$305.15M
Dividend YieldN/A
Average Volume (3M)694.03K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth53.32%
EPS Growth-122.35%
CountryHK
Employees273
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,436,400,000
10 Day Avg. Volume557,500
30 Day Avg. Volume694,033
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)46.59
Price to Sales (P/S)1.12
P/FCF Ratio-9.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compo...
How the Company Makes Money
The company primarily makes money by selling its pharmaceutical and/or medical-related products to customers (e.g., hospitals, pharmacies, distributors, or other healthcare institutions), generating revenue from product sales. Additional revenue s...
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 881.37M | 509.43M | 385.48M | 398.00M | 403.73M | 476.38M |
| Gross Profit | 70.68M | 34.75M | 16.97M | 21.37M | 14.82M | 45.60M |
| EBITDA | -8.26M | -14.08M | -22.11M | 4.79M | -2.26M | -29.86M |
| Net Income | -109.96M | -88.47M | -27.80M | -20.16M | -27.45M | -42.26M |
Balance Sheet | ||||||
| Total Assets | 443.76M | 264.96M | 332.53M | 303.28M | 337.20M | 347.60M |
| Cash, Cash Equivalents and Short-Term Investments | 65.29M | 29.22M | 25.40M | 5.93M | 9.55M | 29.78M |
| Total Debt | 108.79M | 109.79M | 159.92M | 83.56M | 102.61M | 90.34M |
| Total Liabilities | 414.97M | 262.22M | 304.09M | 238.70M | 256.05M | 237.24M |
| Stockholders Equity | 22.43M | 12.23M | 22.15M | 49.95M | 70.11M | 100.78M |
Cash Flow | ||||||
| Free Cash Flow | 106.08M | -62.84M | -28.83M | -15.62M | -21.62M | -40.38M |
| Operating Cash Flow | 119.16M | -54.58M | -26.27M | -13.15M | -12.82M | -6.68M |
| Investing Cash Flow | 34.56M | 31.36M | -37.24M | -467.44K | -12.93M | -8.51M |
| Financing Cash Flow | -75.01M | 27.03M | 82.95M | 12.73M | 6.17M | 28.10M |
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis
Negative
0.40
Price Trends
0.24
Negative
0.20
Negative
0.24
Negative
Market Momentum
-0.03
Positive
19.43
Positive
7.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.24, and above the 200-day MA of 0.24, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 19.43 is Positive, neither overbought nor oversold. The STOCH value of 7.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | HK$4.12B | 4.58 | 13.63% | 4.26% | 0.90% | 16.54% | |
45 Neutral | HK$3.58B | -191.93 | -8.09% | 2.18% | 3.15% | 50.74% | |
43 Neutral | HK$305.15M | -12.37 | -634.56% | ― | 53.32% | -122.35% | |
41 Neutral | HK$48.00M | -0.22 | 14.68% | 3.07% | -45.65% | 29.13% |
* Basic Materials Sector Average
HK:8189
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H
0.14
-0.26
-64.25%
HK:2112
Grace Life-tech Holdings Limited
0.03
-0.03
-48.39%
HK:2198
China Sanjiang Fine Chemicals Co., Ltd.
3.52
1.20
51.51%
HK:0301
SANVO Fine Chemicals Group Limited
7.60
6.35
508.00%
HK:0660
Wai Chun Bio-Technology Ltd.
0.43
0.23
115.00%
HK:2565
PegBio Co., Ltd. Class H
4.09
-56.42
-93.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.